{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:21:52Z","timestamp":1793467312534,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12185-026-04168-4","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T06:26:11Z","timestamp":1769581571000},"page":"858-865","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of diagnosis-to-treatment interval in relapsed or refractory diffuse large B-cell lymphoma"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7872-4226","authenticated-orcid":false,"given":"Keita","family":"Ishii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadahiro","family":"Gunji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Uryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurumi","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riku","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaichi","family":"Nishiwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"4168_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384:842\u201358.","journal-title":"N Engl J Med"},{"key":"4168_CR2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa2116596","volume":"386","author":"MR Bishop","year":"2022","unstructured":"Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2022;386:629\u201339.","journal-title":"N Engl J Med"},{"key":"4168_CR3","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386:640\u201354.","journal-title":"N Engl J Med"},{"key":"4168_CR4","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141:1675\u201384.","journal-title":"Blood"},{"key":"4168_CR5","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387:2220\u201331.","journal-title":"N Engl J Med"},{"key":"4168_CR6","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a Phase I\/II trial. J Clin Oncol. 2023;41:2238\u201347.","journal-title":"J Clin Oncol"},{"key":"4168_CR7","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1182\/bloodadvances.2022009260","volume":"7","author":"NL Bartlett","year":"2023","unstructured":"Bartlett NL, Assouline S, Giri P, Schuster SJ, Cheah CY, Matasar M, et al. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2023;7:4926\u201335.","journal-title":"Blood Adv"},{"key":"4168_CR8","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22:790\u2013800.","journal-title":"Lancet Oncol"},{"key":"4168_CR9","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1200\/JCO.2017.76.5198","volume":"36","author":"MJ Maurer","year":"2018","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Link BK, Jais JP, Habermann TM, Thompson CA, et al. Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials. J Clin Oncol. 2018;36:1603\u201310.","journal-title":"J Clin Oncol"},{"key":"4168_CR10","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1200\/JCO.20.02573","volume":"39","author":"S Alig","year":"2021","unstructured":"Alig S, Macaulay CW, Kurtz DM, D\u00fchrsen U, H\u00fcttmann A, Schmitz C, et al. Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma. J Clin Oncol. 2021;39:2605\u201316.","journal-title":"J Clin Oncol"},{"key":"4168_CR11","first-page":"2493","volume":"141","author":"W Alduaij","year":"2023","unstructured":"Alduaij W, Collinge B, Ben-Neriah S, Jiang A, Hilton LK, Boyle M, et al. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population. Blood. 2023;141:2493\u2013507.","journal-title":"Blood"},{"key":"4168_CR12","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"4168_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275\u201382.","journal-title":"Blood"},{"key":"4168_CR14","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"4168_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"4168_CR16","first-page":"3562","volume":"92","author":"J Blay","year":"1998","unstructured":"Blay J, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C, et al. The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group Blood. 1998;92:3562\u20138.","journal-title":"Parma Group Blood"},{"key":"4168_CR17","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1182\/blood.2023022348","volume":"143","author":"SJ Schuster","year":"2024","unstructured":"Schuster SJ, Huw LY, Bolen CR, Maximov V, Polson AG, Hatzi K, et al. Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed\/refractory B-cell lymphomas. Blood. 2024;143:822\u201332.","journal-title":"Blood"},{"key":"4168_CR18","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1182\/blood-2005-04-1603","volume":"106","author":"CH Moskowitz","year":"2005","unstructured":"Moskowitz CH, Zelenetz AD, Kewalramani T, Hamlin P, Lessac-Chenen S, Houldsworth J, et al. Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. Blood. 2005;106:3383\u20135.","journal-title":"Blood"},{"key":"4168_CR19","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1200\/JCO.2011.35.4423","volume":"29","author":"C Thieblemont","year":"2011","unstructured":"Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, et al. The germinal center\/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed\/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol. 2011;29:4079\u201387.","journal-title":"J Clin Oncol"},{"key":"4168_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/hon.3098","volume":"41","author":"SH Desai","year":"2023","unstructured":"Desai SH, Mwangi R, Smith AN, Maurer MJ, Farooq U, King RL, et al. Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma. Hematol Oncol. 2023;41:39\u201349.","journal-title":"Hematol Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04168-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04168-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04168-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:08:44Z","timestamp":1782468524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04168-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4168"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04168-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"9 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K. Suzuki received personal fees from Janssen Pharmaceutical K.K., Sanofi, Pfizer, Bristol Meyers Squibb, Ono Pharmaceutical Company, and Takeda Pharmaceutical Company, outside the submitted work. T. Gunji received personal fees from Janssen Pharmaceutical K.K., outside the submitted work. H. Uryu received personal fees from Genmab A\/S, and Chugai Pharmaceutical Company, outside the submitted work. R. Nagao received personal fees from Janssen Pharmaceutical K.K. and Sanofi, outside the submitted work. K. Nishiwaki received personal fees from Pfizer, Alexion Pharmaceuticals Inc., Argenx Japan K.K., outside the submitted work. S. Yano received personal fees from Daiichi-Sankyo and AstraZeneca, and reports other financial or non-financial interests with Otsuka Pharmaceutical Company, Kyowa Kirin Company, and Fuji Pharma Company, outside the submitted work. The other authors declare that they have no conflict of interest. Dr. Kazuhito Suzuki is editor of International Journal of Hematology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}